Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT

Sundström Jari; Arola Johanna; Mustonen Harri; Gullichsen Risto; Kauhanen Saila; Vesterinen Tiina; Schildt Jukka; Schalin-Jäntti Camilla; Kemppainen Jukka; Majala Susanna; Seppänen Hanna

Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT

Sundström Jari
Arola Johanna
Mustonen Harri
Gullichsen Risto
Kauhanen Saila
Vesterinen Tiina
Schildt Jukka
Schalin-Jäntti Camilla
Kemppainen Jukka
Majala Susanna
Seppänen Hanna
Katso/Avaa
Publisher's version (1.074Mb)
Lataukset: 

EJNMMI Research
doi:10.1186/s13550-019-0585-7
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042825005
Tiivistelmä

Background: Predicting aggressive behavior of nonfunctional
pancreatic neuroendocrine tumors (NF-PNET) remains controversial. We wanted to
explore, in a prospective setting, whether the diagnostic accuracy can be
improved by dual-tracer functional imaging 68Ga-DOTANOC and 18F-FDG-PET/CT
in patients with NF-PNETs.

Methods: Thirty-one patients with NF-PNET (90% asymptomatic)
underwent PET-imaging with 18F-FDG and 68Ga-DOTANOC,
followed by surgery (n=20), an endoscopic ultrasonography and fine-needle biopsy (n=2) or follow-up (n=9). A focal activity on PET/CT greater
than the background that could not be
identified as physiological activity was considered to indicate tumor tissue. The imaging results were compared to the
histopathology. The mean follow-up time was 31.3 months.

Results: Thirty-one patients presented a total of 53
lesions (40 histologically confirmed) on PET/CT. Thirty patients had a 68Ga-DOTANOC-positive
tumor (sensitivity 97%) and ten patients had an 18F-FDG-positive
tumor. In addition, one 68Ga-DOTANOC-negative patient was 18F-FDG-positive.
18F-FDG-PET/CT was positive in 19%
(3/16) of the G1 tumors, 63% (5/8) of the G2 tumors and 1/1 of the well-differentiated
G3 tumor. 68Ga-DOTANOC-PET/CT was positive in 94% of the G1 tumors,
100% of the G2 tumors and 1/1 of the well-differentiated G3 tumor. Two out of six (33%) of the patients with lymph node
metastases (LN+) were 18F-FDG-positive. The 18F-FDG-PET/CT correlated with
tumor Ki-67 (P=0.021). Further, the
Krenning score correlated with tumor Ki-67 (P=0.013).
18F-FDG-positive tumors were significantly larger than the 18F-FDG-negative
tumors (P=0.012). 18F-FDG-PET/CT
showed a positive predictive value of 78% in the detection of potentially
aggressive tumors (G2, G3 or LN + PNETs); the negative predictive value was
69%.

Conclusions: 18F-FDG-PET/CT is useful to predict
tumor grade but not the LN+ of NF-PNETs. Patients with 18F-FDG-avid NF-PNETs
should be referred for surgery. The 68Ga-DOTANOC-PET/CT also has prognostic value
since the Krenning score predicts the histopathological tumor grade.

Kokoelmat
  • Rinnakkaistallenteet [19207]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste